<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34281199</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>13</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>RAAS: A Convergent Player in Ischemic Heart Failure and Cancer.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7106</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22137106</ELocationID><Abstract><AbstractText>The current global prevalence of heart failure is estimated at 64.34 million cases, and it is expected to increase in the coming years, especially in countries with a medium-low sociodemographic index where the prevalence of risk factors is increasing alarmingly. Heart failure is associated with many comorbidities and among them, cancer has stood out as a contributor of death in these patients. This connection points out new challenges both in the context of the pathophysiological mechanisms involved, as well as in the quality of life of affected individuals. A hallmark of heart failure is chronic activation of the renin-angiotensin-aldosterone system, especially marked by a systemic increase in levels of angiotensin-II, a peptide with pleiotropic activities. Drugs that target the renin-angiotensin-aldosterone system have shown promising results both in the prevention of secondary cardiovascular events in myocardial infarction and heart failure, including a lower risk of certain cancers in these patients, as well as in current cancer therapies; therefore, understanding the mechanisms involved in this complex relationship will provide tools for a better diagnosis and treatment and to improve the prognosis and quality of life of people suffering from these two deadly diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Gardu&#xf1;o</LastName><ForeName>Texali C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0002-7564-4877</Identifier><AffiliationInfo><Affiliation>Centro Universitario de Ciencias de la Salud, Instituto de Investigaci&#xf3;n en Ciencias Biom&#xe9;dicas, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Doctorado en Gen&#xe9;tica Humana, Departamento de Biolog&#xed;a Molecular y Gen&#xf3;mica, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padilla-Gutierrez</LastName><ForeName>Jorge R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-0240-2797</Identifier><AffiliationInfo><Affiliation>Centro Universitario de Ciencias de la Salud, Instituto de Investigaci&#xf3;n en Ciencias Biom&#xe9;dicas, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cambr&#xf3;n-Mora</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Doctorado en Biolog&#xed;a Molecular, Departamento de Biolog&#xed;a Molecular y Gen&#xf3;mica, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>Yeminia</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-4940-022X</Identifier><AffiliationInfo><Affiliation>Centro Universitario de Ciencias de la Salud, Instituto de Investigaci&#xf3;n en Ciencias Biom&#xe9;dicas, Universidad de Guadalajara, Guadalajara 44340, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PROSNI2021</GrantID><Agency>PROSNI - Apoyo a la Mejora en las Condiciones de Producci&#xf3;n SNI y SNCA</Agency><Country/></Grant><Grant><GrantID>PROSNI2021</GrantID><Agency>PROSNI-Apoyo a la Mejora en las Condiciones de Producci&#xf3;n SNI y SNCA</Agency><Country/></Grant><Grant><GrantID>PROSNI2021</GrantID><Agency>PROSNI Apoyo a la Mejora en las Condiciones de Producci&#xf3;n SNI y SNCA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>11128-99-7</RegistryNumber><NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance></Chemical><Chemical><RegistryNumber>4964P6T9RB</RegistryNumber><NameOfSubstance UI="D000450">Aldosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.15</RegistryNumber><NameOfSubstance UI="D012083">Renin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000450" MajorTopicYN="N">Aldosterone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000804" MajorTopicYN="N">Angiotensin II</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017202" MajorTopicYN="N">Myocardial Ischemia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012083" MajorTopicYN="N">Renin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">renin-angiotensin-aldosterone system</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34281199</ArticleId><ArticleId IdType="pmc">PMC8268500</ArticleId><ArticleId IdType="doi">10.3390/ijms22137106</ArticleId><ArticleId IdType="pii">ijms22137106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brancaccio M., Pirozzi F., Hirsch E., Ghigo A. Mechanisms underlying the cross-talk between heart and cancer. J. Physiol. 2020;598:3015&#x2013;3027. doi: 10.1113/JP276746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP276746</ArticleId><ArticleId IdType="pubmed">31278748</ArticleId></ArticleIdList></Reference><Reference><Citation>Papazoglou P., Peng L., Sachinidis A. Epigenetic Mechanisms Involved in the Cardiovascular Toxicity of Anticancer Drugs. Front. Cardiovasc. Med. 2021;8:658900. doi: 10.3389/fcvm.2021.658900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.658900</ArticleId><ArticleId IdType="pmc">PMC8110725</ArticleId><ArticleId IdType="pubmed">33987212</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoltzfus K.C., Zhang Y., Sturgeon K., Sinoway L.I., Trifiletti D.M., Chinchilli V.M., Zaorsky N.G. Fatal heart disease among cancer patients. Nat. Commun. 2020;11:1&#x2013;8. doi: 10.1038/s41467-020-15639-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15639-5</ArticleId><ArticleId IdType="pmc">PMC7181822</ArticleId><ArticleId IdType="pubmed">32332714</ArticleId></ArticleIdList></Reference><Reference><Citation>Banke A., Schou M., Videbaek L., M&#xf8;ller J.E., Torp-Pedersen C., Gustafsson F., Dahl J.S., K&#xf8;ber L., Hildebrandt P.R., Gislason G.H. Incidence of cancer in patients with chronic heart failure: A long-term follow-up study. Eur. J. Heart Fail. 2016;18:260&#x2013;266. doi: 10.1002/ejhf.472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.472</ArticleId><ArticleId IdType="pubmed">26751260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak S., Kwon S., Lee S.Y., Yang S., Lee H.J., Lee H., Park J.B., Han K., Kim Y.J., Kim H.K. Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study. J. Cardiol. 2021;77:231&#x2013;238. doi: 10.1016/j.jjcc.2020.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2020.07.026</ArticleId><ArticleId IdType="pubmed">32863081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasin T., Gerber Y., McNallan S.M., Weston S.A., Kushwaha S.S., Nelson T.J., Cerhan J.R., Roger V.L. Patients with heart failure have an increased risk of incident cancer. J. Am. Coll. Cardiol. 2013;62:881&#x2013;886. doi: 10.1016/j.jacc.2013.04.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.04.088</ArticleId><ArticleId IdType="pmc">PMC3758775</ArticleId><ArticleId IdType="pubmed">23810869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasin T., Gerber Y., Weston S.A., Jiang R., Killian J.M., Manemann S.M., Cerhan J.R., Roger V.L. Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer. J. Am. Coll. Cardiol. 2016;68:265&#x2013;271. doi: 10.1016/j.jacc.2016.04.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.04.053</ArticleId><ArticleId IdType="pmc">PMC4947209</ArticleId><ArticleId IdType="pubmed">27417004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto M., Hasegawa T., Asakura M., Kanzaki H., Takahama H., Amaki M., Mochizuki N., Anzai T., Hamasaki T., Kitakaze M. Does the pathophysiology of heart failure prime the incidence of cancer? Hypertens. Res. 2017;40:831&#x2013;836. doi: 10.1038/hr.2017.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hr.2017.45</ArticleId><ArticleId IdType="pubmed">28381869</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Gao Y., Wang L., Tian L., An N., Yang X., Li X., Tian C., Yuan M., Xiong X., et al. Does heart failure increase the risk of incident cancer? A meta-analysis and systematic review. Heart Fail. Rev. 2020;25:949&#x2013;955. doi: 10.1007/s10741-019-09876-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-019-09876-0</ArticleId><ArticleId IdType="pubmed">31745841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertero E., Ameri P., Maack C. Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology. Card. Fail. Rev. 2019;5:106&#x2013;111. doi: 10.15420/cfr.2019.1.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/cfr.2019.1.2</ArticleId><ArticleId IdType="pmc">PMC6546001</ArticleId><ArticleId IdType="pubmed">31179021</ArticleId></ArticleIdList></Reference><Reference><Citation>Orsborne C., Chaggar P.S., Shaw S.M., Williams S.G. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: The past, the present and the future. Postgrad. Med. J. 2016;93:29&#x2013;37. doi: 10.1136/postgradmedj-2016-134045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2016-134045</ArticleId><ArticleId IdType="pubmed">27671772</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz Ocaranza M., Riquelme J.A., Garc&#xed;a L., Jalil J.E., Chiong M., Santos R.A.S., Lavandero S. Counter-regulatory renin&#x2013;angiotensin system in cardiovascular disease. Nat. Rev. Cardiol. 2020;17:116&#x2013;129. doi: 10.1038/s41569-019-0244-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-019-0244-8</ArticleId><ArticleId IdType="pmc">PMC7097090</ArticleId><ArticleId IdType="pubmed">31427727</ArticleId></ArticleIdList></Reference><Reference><Citation>George A.J., Thomas W.G., Hannan R.D. The renin-angiotensin system and cancer: Old dog, new tricks. Nat. Rev. Cancer. 2010;10:745&#x2013;759. doi: 10.1038/nrc2945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2945</ArticleId><ArticleId IdType="pubmed">20966920</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegman-Ostrosky T., Soto-Reyes E., Vidal-Mill&#xe1;n S., S&#xe1;nchez-Corona J. The renin-angiotensin system meets the hallmarks of cancer. JRAAS J. Renin Angiotensin Aldosterone Syst. 2015;16:227&#x2013;233. doi: 10.1177/1470320313496858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320313496858</ArticleId><ArticleId IdType="pubmed">23934336</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., Fonarow G.C., Geraci S.A., Horwich T., Januzzi J.L., et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;16:e147&#x2013;e239. doi: 10.1161/CIR.0b013e31829e8776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e31829e8776</ArticleId><ArticleId IdType="pubmed">23747642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G., Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med. J. 2020;5:15. doi: 10.21037/amj.2020.03.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/amj.2020.03.03</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgendy I.Y., Mahtta D., Pepine C.J. Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circ. Res. 2019;124:1520&#x2013;1535. doi: 10.1161/CIRCRESAHA.118.313568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.313568</ArticleId><ArticleId IdType="pmc">PMC6534154</ArticleId><ArticleId IdType="pubmed">31120824</ArticleId></ArticleIdList></Reference><Reference><Citation>Roger V.L. Epidemiology of heart failure. Circ. Res. 2013;113:646&#x2013;659. doi: 10.1161/CIRCRESAHA.113.300268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.113.300268</ArticleId><ArticleId IdType="pmc">PMC3806290</ArticleId><ArticleId IdType="pubmed">23989710</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.A., Hashim M.J., Mustafa H., Baniyas M.Y., Al Suwaidi S.K.B.M., AlKatheeri R., Alblooshi F.M.K., Almatrooshi M.E.A.H., Alzaabi M.E.H., Al Darmaki R.S., et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12:e9349. doi: 10.7759/cureus.9349.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.9349</ArticleId><ArticleId IdType="pmc">PMC7384703</ArticleId><ArticleId IdType="pubmed">32742886</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulo G., Igland J., Vollset S.E., Nyg&#xe5;rd O., Ebbing M., Sulo E., Egeland G.M., Tell G.S. Heart failure complicating acute myocardial infarction; burden and timing of occurrence: A nation-wide analysis including 86 771 patients from the cardiovascular disease in norway (CVDNOR) project. J. Am. Heart Assoc. 2016;5:1&#x2013;8. doi: 10.1161/JAHA.115.002667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.115.002667</ArticleId><ArticleId IdType="pmc">PMC4859383</ArticleId><ArticleId IdType="pubmed">26744379</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill T.J., Kharbanda R.K. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk. World J. Cardiol. 2017;9:407. doi: 10.4330/wjc.v9.i5.407.</Citation><ArticleIdList><ArticleId IdType="doi">10.4330/wjc.v9.i5.407</ArticleId><ArticleId IdType="pmc">PMC5442408</ArticleId><ArticleId IdType="pubmed">28603587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jen&#x10d;a D., Melenovsk&#xfd; V., Stehlik J., Stan&#x11b;k V., Kettner J., Kautzner J., Ad&#xe1;mkov&#xe1; V., Wohlfahrt P. Heart failure after myocardial infarction: Incidence and predictors. ESC Heart Fail. 2021;8:222&#x2013;237. doi: 10.1002/ehf2.13144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13144</ArticleId><ArticleId IdType="pmc">PMC7835562</ArticleId><ArticleId IdType="pubmed">33319509</ArticleId></ArticleIdList></Reference><Reference><Citation>Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. Eur. J. Heart Fail. 2020;23:1342&#x2013;1356. doi: 10.1002/ejhf.1858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1858</ArticleId><ArticleId IdType="pmc">PMC7540043</ArticleId><ArticleId IdType="pubmed">32483830</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Colvin M.M., Drazner M.H., Filippatos G.S., Fonarow G.C., Givertz M.M., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137&#x2013;e161. doi: 10.1161/CIR.0000000000000509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000509</ArticleId><ArticleId IdType="pubmed">28455343</ArticleId></ArticleIdList></Reference><Reference><Citation>American Cancer Society  Cancer Facts and Figures 2021.  [(accessed on 27 June 2021)]; Available online:  https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html.</Citation></Reference><Reference><Citation>Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209&#x2013;249. doi: 10.3322/caac.21660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646&#x2013;674. doi: 10.1016/j.cell.2011.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId><ArticleId IdType="pubmed">21376230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameri P., Canepa M., Anker M.S., Belenkov Y., Bergler-Klein J., Cohen-Solal A., Farmakis D., L&#xf3;pez-Fern&#xe1;ndez T., Lainscak M., Pudil R., et al. Cancer diagnosis in patients with heart failure: Epidemiology, clinical implications and gaps in knowledge. Eur. J. Heart Fail. 2018;20:879&#x2013;887. doi: 10.1002/ejhf.1165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1165</ArticleId><ArticleId IdType="pubmed">29464808</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj S., Bhatt D.L., Claggett B., Djouss&#xe9; L., Shah S.J., Chen J., Imran T.F., Qazi S., Sesso H.D., Gaziano J.M., et al. Lack of Association Between Heart Failure and Incident Cancer. J. Am. Coll. Cardiol. 2018;71:1501&#x2013;1510. doi: 10.1016/j.jacc.2018.01.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.01.069</ArticleId><ArticleId IdType="pubmed">29622155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu S., El Khoury N., Rivard K., Paradis P., Nemer M., Fiset C. Angiotensin II Overstimulation Leads to an Increased Susceptibility to Dilated Cardiomyopathy and Higher Mortality in Female Mice. Sci. Rep. 2018;8:7242. doi: 10.1038/s41598-018-19436-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19436-5</ArticleId><ArticleId IdType="pmc">PMC5772611</ArticleId><ArticleId IdType="pubmed">29343862</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S.K., Wruck L., Quibrera M., Matsushita K., Loehr L.R., Chang P.P., Rosamond W.D., Wright J., Heiss G., Coresh J. Temporal trends in hospitalization for acute decompensated heart failure in the United States, 1998&#x2013;2011. Am. J. Epidemiol. 2016;183:462&#x2013;470. doi: 10.1093/aje/kwv455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv455</ArticleId><ArticleId IdType="pmc">PMC4772439</ArticleId><ArticleId IdType="pubmed">26895710</ArticleId></ArticleIdList></Reference><Reference><Citation>Koelwyn G.J., Newman A.A.C., Afonso M.S., van Solingen C., Corr E.M., Brown E.J., Albers K.B., Yamaguchi N., Narke D., Schlegel M., et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat. Med. 2020;26:1452&#x2013;1458. doi: 10.1038/s41591-020-0964-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0964-7</ArticleId><ArticleId IdType="pmc">PMC7789095</ArticleId><ArticleId IdType="pubmed">32661390</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijers W.C., Maglione M., Bakker S.J.L., Oberhuber R., Kieneker L.M., De Jong S., Haubner B.J., Nagengast W.B., Lyon A.R., Van Der Vegt B., et al. Heart failure stimulates tumor growth by circulating factors. Circulation. 2018;138:678&#x2013;691. doi: 10.1161/CIRCULATIONAHA.117.030816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.030816</ArticleId><ArticleId IdType="pubmed">29459363</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen K., Mair J., Giannitsis E., Mueller C., Lindahl B., Blankenberg S., Huber K., Plebani M., Biasucci L.M., Tubaro M., et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur. Heart J. 2012;33:2252&#x2013;2257. doi: 10.1093/eurheartj/ehs154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs154</ArticleId><ArticleId IdType="pubmed">22723599</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliese N.R., Masi S., Taddei S. The renin-angiotensin-aldosterone system: A crossroad from arterial hypertension to heart failure. Heart Fail. Rev. 2020;25:31&#x2013;42. doi: 10.1007/s10741-019-09855-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-019-09855-5</ArticleId><ArticleId IdType="pubmed">31512149</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziaja M., Urbanek K.A., Kowalska K., Piastowska-Ciesielska A.W. Angiotensin II and Angiotensin Receptors 1 and 2&#x2014;Multifunctional System in Cells Biology, What Do We Know? Cells. 2021;10:381. doi: 10.3390/cells10020381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020381</ArticleId><ArticleId IdType="pmc">PMC7917773</ArticleId><ArticleId IdType="pubmed">33673178</ArticleId></ArticleIdList></Reference><Reference><Citation>Steckelings U.M., Paulis L., Namsolleck P., Unger T. AT2 receptor agonists: Hypertension and beyond. Curr. Opin. Nephrol. Hypertens. 2012;21:142&#x2013;146. doi: 10.1097/MNH.0b013e328350261b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MNH.0b013e328350261b</ArticleId><ArticleId IdType="pubmed">22257799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Del Borgo M., Lee H.W., Baraldi D., Hirmiz B., Gaspari T.A., Denton K.M., Aguilar M.I., Samuel C.S., Widdop R.E. Anti-fibrotic potential of AT2 receptor agonists. Front. Pharmacol. 2017;8:564. doi: 10.3389/fphar.2017.00564.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00564</ArticleId><ArticleId IdType="pmc">PMC5583590</ArticleId><ArticleId IdType="pubmed">28912715</ArticleId></ArticleIdList></Reference><Reference><Citation>Rompe F., Artuc M., Hallberg A., Alterman M., Str&#xf6;der K., Th&#xf6;ne-Reineke C., Reichenbach A., Schacherl J., Dahl&#xf6;f B., Bader M., et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor &#x3ba;b. Hypertension. 2010;55:924&#x2013;931. doi: 10.1161/HYPERTENSIONAHA.109.147843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.147843</ArticleId><ArticleId IdType="pubmed">20157051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinter M., Jain R.K. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci. Transl. Med. 2017;9:eaan5616. doi: 10.1126/scitranslmed.aan5616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aan5616</ArticleId><ArticleId IdType="pmc">PMC5928511</ArticleId><ArticleId IdType="pubmed">28978752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh S.P. Encyclopedia of Signaling Molecules. Springer International Publishing; Berlin/Heidelberg, Germany: 2018. Angiotensin Type 2 Receptor; pp. 320&#x2013;327.</Citation></Reference><Reference><Citation>Patel V.B., Zhong J.C., Grant M.B., Oudit G.Y. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ. Res. 2016;118:1313&#x2013;1326. doi: 10.1161/CIRCRESAHA.116.307708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.307708</ArticleId><ArticleId IdType="pmc">PMC4939482</ArticleId><ArticleId IdType="pubmed">27081112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., He W., Guo L., Zhang Y., Li H., Han S., Shen D. The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction. Mol. Med. Rep. 2017;16:1973&#x2013;1981. doi: 10.3892/mmr.2017.6848.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.6848</ArticleId><ArticleId IdType="pmc">PMC5561970</ArticleId><ArticleId IdType="pubmed">28656296</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silveira K.D., Coelho F.M., Vieira A.T., Sachs D., Barroso L.C., Costa V.V., Bretas T.L.B., Bader M., de Sousa L.P., da Silva T.A., et al. Anti-Inflammatory Effects of the Activation of the Angiotensin-(1&#x2013;7) Receptor, Mas, in Experimental Models of Arthritis. J. Immunol. 2010;185:5569&#x2013;5576. doi: 10.4049/jimmunol.1000314.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000314</ArticleId><ArticleId IdType="pubmed">20935211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell M.C., Al Zayadneh E.M. Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways. J. Cell Signal. 2017;2:2. doi: 10.4172/2576-1471.1000134.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2576-1471.1000134</ArticleId><ArticleId IdType="pmc">PMC5501273</ArticleId><ArticleId IdType="pubmed">28691117</ArticleId></ArticleIdList></Reference><Reference><Citation>Park B.M., Cha S.A., Lee S.H., Kim S.H. Angiotensin IV protects cardiac reperfusion injury by inhibiting apoptosis and inflammation via AT4R in rats. Peptides. 2016;79:66&#x2013;74. doi: 10.1016/j.peptides.2016.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2016.03.017</ArticleId><ArticleId IdType="pubmed">27038740</ArticleId></ArticleIdList></Reference><Reference><Citation>de Paula Gonzaga A.L.A.C., Palmeira V.A., Ribeiro T.F.S., Costa L.B., de S&#xe1; Rodrigues K.E., Sim&#xf5;es-e-Silva A.C. ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors. Curr. Drug Targets. 2020;21:892&#x2013;901. doi: 10.2174/1389450121666200210124217.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450121666200210124217</ArticleId><ArticleId IdType="pubmed">32039680</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrester S.J., Booz G.W., Sigmund C.D., Coffman T.M., Kawai T., Rizzo V., Scalia R., Eguchi S. Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology. Physiol. Rev. 2018;98:1627&#x2013;1738. doi: 10.1152/physrev.00038.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00038.2017</ArticleId><ArticleId IdType="pmc">PMC6335102</ArticleId><ArticleId IdType="pubmed">29873596</ArticleId></ArticleIdList></Reference><Reference><Citation>Emdin M., Fatini C., Mirizzi G., Poletti R., Borrelli C., Prontera C., Latini R., Passino C., Clerico A., Vergaro G. Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: How useful, how feasible? Clin. Chim. Acta. 2015;443:85&#x2013;93. doi: 10.1016/j.cca.2014.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2014.10.031</ArticleId><ArticleId IdType="pubmed">25445411</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta P., Courties G., Wei Y., Leuschner F., Gorbatov R., Robbins C.S., Iwamoto Y., Thompson B., Carlson A.L., Heidt T., et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325&#x2013;329. doi: 10.1038/nature11260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11260</ArticleId><ArticleId IdType="pmc">PMC3401326</ArticleId><ArticleId IdType="pubmed">22763456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyaw T., Loveland P., Kanellakis P., Cao A., Kallies A., Huang A.L., Peter K., Toh B.-H., Bobik A. Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms. Eur. Heart J. 2021;42:938&#x2013;947. doi: 10.1093/eurheartj/ehaa995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa995</ArticleId><ArticleId IdType="pubmed">33338208</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasini E., Cosentino M., Marino F., Legnaro M., Ferrari M., Guasti L., Venco A., Lecchini S. Angiotensin II type 1 receptor expression on human leukocyte subsets: A flow cytometric and RT-PCR study. Regul. Pept. 2006;134:69&#x2013;74. doi: 10.1016/j.regpep.2006.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.regpep.2006.01.007</ArticleId><ArticleId IdType="pubmed">16530863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Zingler M., Harrison J.K., Scott E.W., Cogle C.R., Luo D., Raizada M.K. Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells. Hypertension. 2016;67:574&#x2013;584. doi: 10.1161/HYPERTENSIONAHA.115.06474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.06474</ArticleId><ArticleId IdType="pmc">PMC4752412</ArticleId><ArticleId IdType="pubmed">26781279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez-Retamozo V., Etzrodt M., Newton A., Ryan R., Pucci F., Sio S.W., Kuswanto W., Rauch P.J., Chudnovskiy A., Iwamoto Y., et al. Angiotensin II Drives the Production of Tumor-Promoting Macrophages. Immunity. 2013;38:296&#x2013;308. doi: 10.1016/j.immuni.2012.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.10.015</ArticleId><ArticleId IdType="pmc">PMC3582771</ArticleId><ArticleId IdType="pubmed">23333075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudi W.-S., Molitor M., Garlapati V., Finger S., Wild J., M&#xfc;nzel T., Karbach S.H., Wenzel P. ACE Inhibition Modulates Myeloid Hematopoiesis after Acute Myocardial Infarction and Reduces Cardiac and Vascular Inflammation in Ischemic Heart Failure. Antioxidants. 2021;10:396. doi: 10.3390/antiox10030396.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10030396</ArticleId><ArticleId IdType="pmc">PMC8001011</ArticleId><ArticleId IdType="pubmed">33807982</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangogiannis N.G. The immune system and the remodeling infarcted heart: Cell biological insights and therapeutic opportunities. J. Cardiovasc. Pharmacol. 2014;63:185&#x2013;195. doi: 10.1097/FJC.0000000000000003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000000003</ArticleId><ArticleId IdType="pmc">PMC3949163</ArticleId><ArticleId IdType="pubmed">24072174</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P., Nahrendorf M., Swirski F.K. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease an expanded cardiovascular continuum. J. Am. Coll. Cardiol. 2016;67:1091&#x2013;1103. doi: 10.1016/j.jacc.2015.12.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.12.048</ArticleId><ArticleId IdType="pmc">PMC4779182</ArticleId><ArticleId IdType="pubmed">26940931</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz S.D. In: Mechanisms of Heart Failure BT&#x2014;Management of Heart Failure: Volume 1: Medical. Baliga R.R., Haas G.J., editors. Springer; London, UK: 2015. pp. 13&#x2013;30.</Citation></Reference><Reference><Citation>Dewey C.M., Spitler K.M., Ponce J.M., Hall D.D., Grueter C.E. Cardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers. J. Am. Heart Assoc. 2016;5:e003101. doi: 10.1161/JAHA.115.003101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.115.003101</ArticleId><ArticleId IdType="pmc">PMC4937259</ArticleId><ArticleId IdType="pubmed">27247337</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67:9518&#x2013;9527. doi: 10.1158/0008-5472.CAN-07-0175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-07-0175</ArticleId><ArticleId IdType="pubmed">17909062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss M., Caro A.A., Raes G., Laoui D. Systemic Reprogramming of Monocytes in Cancer. Front. Oncol. 2020;10:1399. doi: 10.3389/fonc.2020.01399.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.01399</ArticleId><ArticleId IdType="pmc">PMC7528630</ArticleId><ArticleId IdType="pubmed">33042791</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N., Baby D., Rajguru J., Patil P., Thakkannavar S., Pujari V. Inflammation and cancer. Ann. Afr. Med. 2019;18:121&#x2013;126. doi: 10.4103/aam.aam_56_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/aam.aam_56_18</ArticleId><ArticleId IdType="pmc">PMC6704802</ArticleId><ArticleId IdType="pubmed">31417011</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson N.M., Simon M.C. The tumor microenvironment. Curr. Biol. 2020;30:R921&#x2013;R925. doi: 10.1016/j.cub.2020.06.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2020.06.081</ArticleId><ArticleId IdType="pmc">PMC8194051</ArticleId><ArticleId IdType="pubmed">32810447</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin M.N., Siddiqui S.A., Ibrahim M., Hakim M.L., Ahammed M.S., Kabir A., Sultana F. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Med. 2020;8:2050312120965752. doi: 10.1177/2050312120965752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050312120965752</ArticleId><ArticleId IdType="pmc">PMC7594225</ArticleId><ArticleId IdType="pubmed">33194199</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher U.M., Endtmann C., Tiyerili V., Nickenig G., Werner N. Endothelial damage and regeneration: The role of the renin-angiotensin- aldosterone system. Curr. Hypertens. Rep. 2011;13:86&#x2013;92. doi: 10.1007/s11906-010-0171-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-010-0171-x</ArticleId><ArticleId IdType="pubmed">21108024</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva G.M., Fran&#xe7;a-Falc&#xe3;o M.S., Calzerra N.T.M., Luz M.S., Gadelha D.D.A., Balarini C.M., Queiroz T.M. Role of Renin-Angiotensin System Components in Atherosclerosis: Focus on Ang-II, ACE2, and Ang-1&#x2013;7. Front. Physiol. 2020;11:1067. doi: 10.3389/fphys.2020.01067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.01067</ArticleId><ArticleId IdType="pmc">PMC7494970</ArticleId><ArticleId IdType="pubmed">33013457</ArticleId></ArticleIdList></Reference><Reference><Citation>Davel A.P., Anwar I.J., Jaffe I.Z. The endothelial mineralocorticoid receptor: Mediator of the switch from vascular health to disease. Curr. Opin. Nephrol. Hypertens. 2017;26:97&#x2013;104. doi: 10.1097/MNH.0000000000000306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MNH.0000000000000306</ArticleId><ArticleId IdType="pmc">PMC5382958</ArticleId><ArticleId IdType="pubmed">27930384</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera-Zelada N., Zu&#xf1;iga-Cuevas U., Ramirez-Reyes A., Lavandero S., Riquelme J.A. Targeting the Endothelium to Achieve Cardioprotection. Front. Pharmacol. 2021;12:3. doi: 10.3389/fphar.2021.636134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.636134</ArticleId><ArticleId IdType="pmc">PMC7884828</ArticleId><ArticleId IdType="pubmed">33603675</ArticleId></ArticleIdList></Reference><Reference><Citation>Toya T., Sara J.D., Corban M.T., Taher R., Godo S., Herrmann J., Lerman L.O., Lerman A. Assessment of peripheral endothelial function predicts future risk of solid-tumor cancer. Eur. J. Prev. Cardiol. 2020;27:608&#x2013;618. doi: 10.1177/2047487319884246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487319884246</ArticleId><ArticleId IdType="pubmed">31668110</ArticleId></ArticleIdList></Reference><Reference><Citation>Franses J.W., Drosu N.C., Gibson W.J., Chitalia V.C., Edelman E.R. Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis. Int. J. Cancer. 2013;133:1334&#x2013;1344. doi: 10.1002/ijc.28146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.28146</ArticleId><ArticleId IdType="pmc">PMC3707950</ArticleId><ArticleId IdType="pubmed">23463345</ArticleId></ArticleIdList></Reference><Reference><Citation>Molitor M., Rudi W.S., Garlapati V., Finger S., Sch&#xfc;ler R., Kossmann S., Lagrange J., Nguyen T.S., Wild J., Knopp T., et al. Nox2+myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1. Cardiovasc. Res. 2021;117:162&#x2013;177. doi: 10.1093/cvr/cvaa042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa042</ArticleId><ArticleId IdType="pubmed">32077922</ArticleId></ArticleIdList></Reference><Reference><Citation>Catarata M.J., Ribeiro R., Oliveira M.J., Cordeiro C.R., Medeiros R. Renin-angiotensin system in lung tumor and microenvironment interactions. Cancers. 2020;12:1457. doi: 10.3390/cancers12061457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12061457</ArticleId><ArticleId IdType="pmc">PMC7352181</ArticleId><ArticleId IdType="pubmed">32503281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikane S., Takahashi-Yanaga F. The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis. Biochem. Pharmacol. 2018;151:96&#x2013;103. doi: 10.1016/j.bcp.2018.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2018.03.008</ArticleId><ArticleId IdType="pubmed">29534876</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L.-H., Sun H.-C., Zhu X.-D., Zhang S.-Z., Li X.-L., Li K.-S., Liu X.-F., Lei M., Li Y., Tang Z.-Y. Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma. Ann. Transl. Med. 2021;9:207. doi: 10.21037/atm-20-5293.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-5293</ArticleId><ArticleId IdType="pmc">PMC7940954</ArticleId><ArticleId IdType="pubmed">33708834</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R.B., Colangelo L.A., Bielinski S.J., Larson N.B., Ding J., Allen N.B., Michos E.D., Shah S.J., Lloyd-Jones D.M. Circulating Vascular Cell Adhesion Molecule-1 and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA) J. Am. Heart Assoc. 2020;9:e019390. doi: 10.1161/JAHA.120.019390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.019390</ArticleId><ArticleId IdType="pmc">PMC7763727</ArticleId><ArticleId IdType="pubmed">33161805</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbajo-Lozoya J., Lutz S., Feng Y., Kroll J., Hammes H.P., Wieland T. Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. Cell. Signal. 2012;24:1261&#x2013;1269. doi: 10.1016/j.cellsig.2012.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2012.02.005</ArticleId><ArticleId IdType="pubmed">22374305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesp&#xf3;n-Fern&#xe1;ndez M., Raposeiras-Roub&#xed;n S., Abu-Assi E., Manzano-Fern&#xe1;ndez S., Flores-Blanco P., Barreiro-Pardal C., Casti&#xf1;eira-Busto M., Mu&#xf1;oz-Pousa I., L&#xf3;pez-Rodr&#xed;guez E., Caneiro-Queija B., et al. Renin&#x2013;Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study. Am. J. Cardiovasc. Drugs. 2019;19:487&#x2013;495. doi: 10.1007/s40256-019-00343-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-019-00343-7</ArticleId><ArticleId IdType="pubmed">30924021</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposeiras-Roub&#xed;n S., Abu-Assi E., Cesp&#xf3;n-Fern&#xe1;ndez M., Ib&#xe1;&#xf1;ez B., Garc&#xed;a-Ruiz J.M., D&#x2019;Ascenzo F., Simao Henriques J.P., Saucedo J., Caneiro-Queija B., Cobas-Paz R., et al. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction. Rev. Esp. Cardiol. 2020;73:114&#x2013;122. doi: 10.1016/j.recesp.2019.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2019.02.017</ArticleId><ArticleId IdType="pubmed">31105064</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim H.W., Zheng H., Richards A.M., Chen R.W., Sahlen A., Yeo K.K., Tan J.W., Chua T., Tan H.C., Yeo T.C., et al. Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization. Sci. Rep. 2020;10:15184. doi: 10.1038/s41598-020-72232-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72232-y</ArticleId><ArticleId IdType="pmc">PMC7495427</ArticleId><ArticleId IdType="pubmed">32938986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar R., Shafiee M., Hesari A.R., Ferns G.A., Ghasemi F., Avan A. The potential therapeutic use of renin&#x2013;angiotensin system inhibitors in the treatment of inflammatory diseases. J. Cell. Physiol. 2019;234:2277&#x2013;2295. doi: 10.1002/jcp.27205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27205</ArticleId><ArticleId IdType="pubmed">30191985</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R., Zhang Y., Liao X., Yao Y., Huang C., Liu L. The Relationship Between Anti-Hypertensive Drugs and Cancer: Anxiety to be Resolved in Urgent. Front. Pharmacol. 2020;11:2122. doi: 10.3389/fphar.2020.610157.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.610157</ArticleId><ArticleId IdType="pmc">PMC7768037</ArticleId><ArticleId IdType="pubmed">33381045</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer M.A., Braunwald E., Moy&#xe9; L.A., Basta L., Brown E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., et al. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N. Engl. J. Med. 1992;327:669&#x2013;677. doi: 10.1056/NEJM199209033271001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199209033271001</ArticleId><ArticleId IdType="pubmed">1386652</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronow W.S., Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am. J. Cardiol. 1993;71:602&#x2013;604. doi: 10.1016/0002-9149(93)90520-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(93)90520-M</ArticleId><ArticleId IdType="pubmed">8438750</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Gray C.S., Lye M., O&#x2019;Mahony D., Polonski L., Taylor J. Perindopril for elderly people with chronic heart failure: The PEP-CHF study. Eur. J. Heart Fail. 1999;1:211&#x2013;217. doi: 10.1016/S1388-9842(99)00039-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1388-9842(99)00039-2</ArticleId><ArticleId IdType="pubmed">10935667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: Results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch. Intern. Med. 2006;166:659&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567606</ArticleId></ArticleIdList></Reference><Reference><Citation>The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">8104270</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper D., Greenberg S. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Cardiovasc. Rev. Rep. 1996;17:49.</Citation></Reference><Reference><Citation>The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Yusuf S., Teo K., Anderson C., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372:1174&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">18757085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., Michelson E.L., Olofsson B., &#xd6;stergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial. Lancet. 2003;362:777&#x2013;781. doi: 10.1016/S0140-6736(03)14285-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)14285-7</ArticleId><ArticleId IdType="pubmed">13678871</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer M.A., McMurray J.J., &#xd6;stergren J., Granger C.B., Yusuf S., Pitt B. Candesartan reduced mortality and hospital admissions in chronic heart failure. Evid. Based. Med. 2004;9:44&#x2013;45.</Citation></Reference><Reference><Citation>Konstam M.A., Neaton J.D., Dickstein K., Drexler H., Komajda M., Martinez F.A., Riegger G.A., Malbecq W., Smith R.D., Guptha S., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet. 2009;374:1840&#x2013;1848. doi: 10.1016/S0140-6736(09)61913-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61913-9</ArticleId><ArticleId IdType="pubmed">19922995</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer M.A., McMurray J., Leizorovicz A., Maggioni A.P., Rouleau J.L., Van De Werf F., Henis M., Neuhart E., Gallo P., Edwards S., et al. Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design. Am. Heart J. 2000;140:727&#x2013;750. doi: 10.1067/mhj.2000.108832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mhj.2000.108832</ArticleId><ArticleId IdType="pubmed">11054617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bissessor N., White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc. Health Risk Manag. 2007;3:425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291334</ArticleId><ArticleId IdType="pubmed">17969373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi M., Tsutamoto T., Wada A., Tsutsui T., Ishii C., Ohno K., Fujii M., Taniguchi A., Hamatani T., Nozato Y., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559&#x2013;2565.</Citation><ArticleIdList><ArticleId IdType="pubmed">12732605</ArticleId></ArticleIdList></Reference><Reference><Citation>Song T., Choi C.H., Kim M.K., Kim M.L., Yun B.S., Seong S.J. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis. Eur. J. Cancer Prev. 2017;26:78&#x2013;85. doi: 10.1097/CEJ.0000000000000269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CEJ.0000000000000269</ArticleId><ArticleId IdType="pubmed">27158979</ArticleId></ArticleIdList></Reference><Reference><Citation>Asgharzadeh F., Hashemzehi M., Moradi-Marjaneh R., Hassanian S.M., Ferns G.A., Khazaei M., Avan A. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis. Life Sci. 2020;242:117181. doi: 10.1016/j.lfs.2019.117181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.117181</ArticleId><ArticleId IdType="pubmed">31863771</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Chen D.-S., Xin L., Zhou L.-Q., Zhang H.-T., Liu L., Yuan Y.-W., Li S.-H. The renin&#x2013;angiotensin system blockers and survival in digestive system malignancies. Medicine. 2020;99:e19075. doi: 10.1097/MD.0000000000019075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000019075</ArticleId><ArticleId IdType="pmc">PMC7035076</ArticleId><ArticleId IdType="pubmed">32049809</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang K., Zhang Y., Liu W., He C. Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: A meta-analysis of randomized controlled trials. Heart Fail. Rev. 2021;26:101&#x2013;109. doi: 10.1007/s10741-019-09906-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-019-09906-x</ArticleId><ArticleId IdType="pubmed">31900787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Cai S.R., Zhang C.H., He Y.L., Zhan W.H., Wu H., Peng J.J. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin. Med. J. 2008;121:2167&#x2013;2171. doi: 10.1097/00029330-200811010-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00029330-200811010-00012</ArticleId><ArticleId IdType="pubmed">19080179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasha F., Kahathuduwa C., Ramalingam L., Hernandez A., Moussa H., Moustaid-Moussa N. Combined Effects of Eicosapentaenoic Acid and Adipocyte Renin&#x2013;Angiotensin System Inhibition on Breast Cancer Cell Inflammation and Migration. Cancers. 2020;12:220. doi: 10.3390/cancers12010220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12010220</ArticleId><ArticleId IdType="pmc">PMC7016836</ArticleId><ArticleId IdType="pubmed">31963198</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Iglesia I&#xf1;igo S., L&#xf3;pez-Jorge C.E., G&#xf3;mez-Casares M.T., Lemes Castellano A., Mart&#xed;n Cabrera P., L&#xf3;pez Brito J., Su&#xe1;rez Cabrera A., Molero Labarta T. Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: A new role in the treatment of leukaemia for these agents. Leuk. Res. 2009;33:810&#x2013;816. doi: 10.1016/j.leukres.2008.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2008.09.029</ArticleId><ArticleId IdType="pubmed">19010543</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui T., Chiyo T., Kobara H., Fujihara S., Fujita K., Namima D., Nakahara M., Kobayashi N., Nishiyama N., Yachida T., et al. Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo. Int. J. Mol. Sci. 2019;20:3197. doi: 10.3390/ijms20133197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133197</ArticleId><ArticleId IdType="pmc">PMC6651359</ArticleId><ArticleId IdType="pubmed">31261874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosugi M., Miyajima A., Kikuchi E., Kosaka T., Horiguchi Y., Murai M. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Hum. Cell. 2007;20:1&#x2013;9. doi: 10.1111/j.1749-0774.2007.00025.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-0774.2007.00025.x</ArticleId><ArticleId IdType="pubmed">17506771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasheduzzaman M., Park S.Y. Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux. Exp. Cell Res. 2018;368:126&#x2013;135. doi: 10.1016/j.yexcr.2018.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2018.04.022</ArticleId><ArticleId IdType="pubmed">29694835</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan D.P., Coy J.W., Chahal K.K., Chow L., Kurihara J.N., Guth A.M., Kufareva I., Dow S.W. The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment. J. Immunol. 2019;202:3087&#x2013;3102. doi: 10.4049/jimmunol.1800619.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800619</ArticleId><ArticleId IdType="pmc">PMC6504574</ArticleId><ArticleId IdType="pubmed">30971441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemzehi M., Naghibzadeh N., Asgharzadeh F., Mostafapour A., Hassanian S.M., Ferns G.A., Cho W.C., Avan A., Khazaei M. The therapeutic potential of losartan in lung metastasis of colorectal cancer. EXCLI J. 2020;19:927&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7355150</ArticleId><ArticleId IdType="pubmed">32665776</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold A., Eini L., Nissim-Rafinia M., Viner R., Ezer S., Erez K., Aqaqe N., Hanania R., Milyavsky M., Meshorer E., et al. Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response. Oncogene. 2019;38:3103&#x2013;3118. doi: 10.1038/s41388-018-0654-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-018-0654-9</ArticleId><ArticleId IdType="pubmed">30622338</ArticleId></ArticleIdList></Reference><Reference><Citation>Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J. Natl. Cancer Inst. 2010;102:14&#x2013;25. doi: 10.1093/jnci/djp440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djp440</ArticleId><ArticleId IdType="pmc">PMC2802286</ArticleId><ArticleId IdType="pubmed">20007921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalam K., Marwick T.H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur. J. Cancer. 2013;49:2900&#x2013;2909. doi: 10.1016/j.ejca.2013.04.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2013.04.030</ArticleId><ArticleId IdType="pubmed">23706982</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez I.E., Taveras Alam S., Hernandez G.A., Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin. Med. Insights Cardiol. 2019;13:13. doi: 10.1177/1179546819866445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1179546819866445</ArticleId><ArticleId IdType="pmc">PMC6664629</ArticleId><ArticleId IdType="pubmed">31384135</ArticleId></ArticleIdList></Reference><Reference><Citation>Tini G., Bertero E., Signori A., Sormani M.P., Maack C., De Boer R.A., Canepa M., Ameri P. Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc. 2020;9 doi: 10.1161/JAHA.119.016309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.016309</ArticleId><ArticleId IdType="pmc">PMC7726990</ArticleId><ArticleId IdType="pubmed">32862764</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Hassan D., Aldawsari H.M., Molugulu N., Shukla R., Kesharwani P. Immune checkpoint inhibitors: A promising anticancer therapy. Drug Discov. Today. 2020;25:223&#x2013;229. doi: 10.1016/j.drudis.2019.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2019.11.003</ArticleId><ArticleId IdType="pubmed">31738877</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil D.N., Smith E.L., Brentjens R.J., Wolchok J.D. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 2016;13:273&#x2013;290. doi: 10.1038/nrclinonc.2016.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2016.25</ArticleId><ArticleId IdType="pmc">PMC5551685</ArticleId><ArticleId IdType="pubmed">26977780</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 2019;38:1&#x2013;12. doi: 10.1186/s13046-019-1259-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-019-1259-z</ArticleId><ArticleId IdType="pmc">PMC6567914</ArticleId><ArticleId IdType="pubmed">31196207</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie G., Cheng T., Lin J., Zhang L., Zheng J., Liu Y., Xie G., Wang B., Yuan Y. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. J. Immunother. Cancer. 2018;6:1&#x2013;14. doi: 10.1186/s40425-018-0401-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-018-0401-3</ArticleId><ArticleId IdType="pmc">PMC6134794</ArticleId><ArticleId IdType="pubmed">30208943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D.S., Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321&#x2013;330. doi: 10.1038/nature21349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21349</ArticleId><ArticleId IdType="pubmed">28102259</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Tomczak K., Li J., Ochieng J.K., Lee Y., Haymaker C. Next-Generation Immunotherapies to Improve Anticancer Immunity. Front. Pharmacol. 2021;11:1947. doi: 10.3389/fphar.2020.566401.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.566401</ArticleId><ArticleId IdType="pmc">PMC7831045</ArticleId><ArticleId IdType="pubmed">33505304</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37360897</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2628-491X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Advances in laboratory medicine</Title><ISOAbbreviation>Adv Lab Med</ISOAbbreviation></Journal><ArticleTitle>El laboratorio en el diagn&#xf3;stico multidisciplinar del desarrollo sexual an&#xf3;malo o diferente (DSD): III) Marcadores bioqu&#xed;micos y gen&#xe9;ticos en los 46,XY IV) Propuestas para el diagn&#xf3;stico diferencial de los DSD.</ArticleTitle><Pagination><StartPage>494</StartPage><EndPage>515</EndPage><MedlinePgn>494-515</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/almed-2020-0120</ELocationID><Abstract><AbstractText Label="OBJETIVOS" NlmCategory="UNASSIGNED">El desarrollo sexual an&#xf3;malo o diferente (DSD) con cariotipo 46,XY incluye anomal&#xed;as en el desarrollo gonadal y/o genital (externo y/o interno).</AbstractText><AbstractText Label="CONTENIDO" NlmCategory="UNASSIGNED">Los marcadores bioqu&#xed;micos &#xfa;tiles para el diagn&#xf3;stico diferencial de los DSD con cariotipo 46,XY incluyen las hormonas del eje hipot&#xe1;lamo-hip&#xf3;fiso gonadal como son las gonadotropinas LH y FSH (en condiciones basales o tras la estimulaci&#xf3;n con LHRH), la hormona anti-M&#xfc;lleriana, la inhibina B, el factor insulinoide tipo 3&#xa0;y las hormonas esteroideas de origen suprarrenal (se incluir&#xe1; la hormona hipofisaria ACTH) y testicular (cortisol, aldosterona y sus precursores, testosterona y sus precursores, dihidrotestosterona y estradiol). Las hormonas esteroideas se analizar&#xe1;n en condiciones basales o tras la estimulaci&#xf3;n con ACTH (hormonas adrenales) y/o con HCG (hormonas testiculares). Los patrones de variaci&#xf3;n de las distintas hormonas depender&#xe1;n de la causa y la edad de cada paciente. El diagn&#xf3;stico molecular debe incluir el an&#xe1;lisis de un gen candidato, un panel de genes o el an&#xe1;lisis de un exoma completo.</AbstractText><AbstractText Label="PERSPECTIVAS" NlmCategory="UNASSIGNED">El diagn&#xf3;stico diferencial de los DSD con cariotipos 46,XX &#xf3; 46,XY debe ser multidisciplinar, incluyendo los antecedentes cl&#xed;nicos, morfol&#xf3;gicos, de imagen, bioqu&#xed;micos y gen&#xe9;ticos. Se han elaborado numerosos algoritmos diagn&#xf3;sticos.</AbstractText><CopyrightInformation>&#xa9; 2021 Maria Luisa Granada and Laura Aud&#xed;, published by De Gruyter, Berlin/Boston.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Granada</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-6816-7566</Identifier><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Hospital Germans Trias i Pujol, Autonomous University of Barcelona, Badalona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aud&#xed;</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Growth and Development Research Group, Vall d'Hebron Research Institute (VHIR), Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Catalonia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Adv Lab Med</MedlineTA><NlmUniqueID>9918284273306676</NlmUniqueID><ISSNLinking>2628-491X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DSD 46,XY</Keyword><Keyword MajorTopicYN="N">algoritmo diagn&#xf3;stico</Keyword><Keyword MajorTopicYN="N">desarrollo sexual an&#xf3;malo o diferente (DSD)</Keyword><Keyword MajorTopicYN="N">diagn&#xf3;stico bioqu&#xed;mico</Keyword><Keyword MajorTopicYN="N">diagn&#xf3;stico gen&#xe9;tico</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37360897</ArticleId><ArticleId IdType="pmc">PMC10197789</ArticleId><ArticleId IdType="doi">10.1515/almed-2020-0120</ArticleId><ArticleId IdType="pii">almed-2020-0120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wherrett DK. Approach to the infant with a suspected disorder of sex development. Pediatr Clin. 2015;62:983&#x2013;99. doi: 10.1016/j.pcl.2015.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcl.2015.04.011</ArticleId><ArticleId IdType="pubmed">26210628</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinspon RP, Loreti N, Braslavsky D, Valeri C, Schteingart H, Ballerini MG, et al. Spreading the clinical window for diagnosing fetal-onset hypogonadism in boys. Front Endocrinol. 2014;5:51. doi: 10.3389/fendo.2014.00051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2014.00051</ArticleId><ArticleId IdType="pmc">PMC4019849</ArticleId><ArticleId IdType="pubmed">24847309</ArticleId></ArticleIdList></Reference><Reference><Citation>Forest MG, Cathiard AM, Bertrand JA. Evidence of testicular activity in early infancy. J Clin Endocrinol Metab. 1973;37:148&#x2013;51. doi: 10.1210/jcem-37-1-148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem-37-1-148</ArticleId><ArticleId IdType="pubmed">4715291</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey RA. Biomarcadores de hipogonadismo masculino en la infancia y la adolescencia. Adv Lab Med. 2020;1 doi: 10.1515/almed-2019-0043. 20190043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/almed-2019-0043</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelsztein NY, Grinspon RP, Schteingart HF, Rey RA. Anti-M&#xfc;llerian hormone as a marker of steroid and gonadotropin action in the testis of children and adolescents with disorders of the gonadal axis. Int J Pediatr Endocrinol. 2016;20 doi: 10.1186/s13633-016-0038-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13633-016-0038-2</ArticleId><ArticleId IdType="pmc">PMC5084469</ArticleId><ArticleId IdType="pubmed">27799946</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksglaede L, S&#xf8;rensen K, Boas M, Mouritsen A, Hagen CP, Jensen RB, et al. Changes in anti-M&#xfc;llerian hormone (AMH) throughout the life span: a population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. J Clin Endocrinol Metab. 2010;95:5357&#x2013;64. doi: 10.1210/jc.2010-1207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2010-1207</ArticleId><ArticleId IdType="pubmed">20843948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergad&#xe1; I, Rojas G, Ropelato G, Ayuso S, Bergad&#xe1; C, Campo S. Sexual dimorphism in circulating monomeric and dimeric inhibins in normal boys and girls from birth to puberty. Clin Endocrinol. 1999;51:455&#x2013;60. doi: 10.1046/j.1365-2265.1999.00814.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2265.1999.00814.x</ArticleId><ArticleId IdType="pubmed">10583312</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire AV, Grinspon RP, Rey RA. Importance of serum testicular protein hormone measurement in the assessment of disorders of sex development. Sex Dev. 2018;12:30&#x2013;40. doi: 10.1159/000479572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000479572</ArticleId><ArticleId IdType="pubmed">28850950</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranowski ES, Arlt W, Idkowiak J. Monogenic disorders of adrenal steroidogenesis. Horm Res Paediatr. 2018;89:292&#x2013;310. doi: 10.1159/000488034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000488034</ArticleId><ArticleId IdType="pmc">PMC6067656</ArticleId><ArticleId IdType="pubmed">29874650</ArticleId></ArticleIdList></Reference><Reference><Citation>Latronico AC, Arnhold IJ. Gonadotropin resistance. Endocr Dev. 2013;24:25&#x2013;32. doi: 10.1159/000342496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000342496</ArticleId><ArticleId IdType="pubmed">23392092</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Xu X, Kong L, Zhou F, Zhao S, Xin X, et al. Novel homozygous nonsense mutations in LHCGR lead to empty follicle syndrome and 46,XY disorder of sex development. Hum Reprod. 2018;33:1364&#x2013;9. doi: 10.1093/humrep/dey215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/dey215</ArticleId><ArticleId IdType="pubmed">29912377</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter FD. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet. 2008;16:535&#x2013;41. doi: 10.1038/ejhg.2008.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2008.10</ArticleId><ArticleId IdType="pubmed">18285838</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WL. Disorders of androgen synthesis--from cholesterol to dehydroepiandrosterone. Med Princ Pract. 2005;14(1 Suppl):58&#x2013;68. doi: 10.1159/000086185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000086185</ArticleId><ArticleId IdType="pubmed">16103714</ArticleId></ArticleIdList></Reference><Reference><Citation>Metherell LA, Naville D, Halaby G, Begeot M, Huebner A, N&#xfc;rnberg G, et al. Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency. J Clin Endocrinol Metab. 2009;94:3865&#x2013;71. doi: 10.1210/jc.2009-0467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2009-0467</ArticleId><ArticleId IdType="pmc">PMC2860769</ArticleId><ArticleId IdType="pubmed">19773404</ArticleId></ArticleIdList></Reference><Reference><Citation>Auchus RJ. Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. J Steroid Biochem Mol Biol. 2017;165:71&#x2013;8. doi: 10.1016/j.jsbmb.2016.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2016.02.002</ArticleId><ArticleId IdType="pmc">PMC4976049</ArticleId><ArticleId IdType="pubmed">26862015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt MR, Khatri Y, Rodgers RJ, Martin LL. Role of cytochrome b5 in the modulation of the enzymatic activities of cytochrome P450 17&#x3b1;-hydroxylase/17,20-lyase (P450 17A1) J Steroid Biochem Mol Biol. 2017;170:2&#x2013;18. doi: 10.1016/j.jsbmb.2016.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2016.02.033</ArticleId><ArticleId IdType="pubmed">26976652</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhard FZ, Parween S, Udhane SS, Fl&#xfc;ck CE, Pandey AV. P450 Oxidoreductase deficiency: analysis of mutations and polymorphisms. J Steroid Biochem Mol Biol. 2017;165:38&#x2013;50. doi: 10.1016/j.jsbmb.2016.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2016.04.003</ArticleId><ArticleId IdType="pubmed">27068427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok RC, Timmerman MA, Wolffenbuttel KP, Drop SL, de Jong FH. Isolated 17,20-lyase deficiency due to the cytochrome b5 mutation W27X. J Clin Endocrinol Metab. 2010;95:994&#x2013;9. doi: 10.1210/jc.2008-1745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2008-1745</ArticleId><ArticleId IdType="pubmed">20080843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fl&#xfc;ck CE, Meyer-B&#xf6;ni M, Pandey AV, Kempn&#xe1; P, Miller WL, Schoenle EJ, et al. Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet. 2011;89:201&#x2013;18. doi: 10.1016/j.ajhg.2011.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.06.009</ArticleId><ArticleId IdType="pmc">PMC3155178</ArticleId><ArticleId IdType="pubmed">21802064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mares L, Vilchis F, Ch&#xe1;vez B, Ramos L. Molecular genetic analysis of AKR1C2-4 and HSD17B6 genes in subjects 46,XY with hypospadias. J Pediatr Urol. 2020;16:e1&#x2013;12. doi: 10.1016/j.jpurol.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpurol.2020.07.001</ArticleId><ArticleId IdType="pubmed">32732174</ArticleId></ArticleIdList></Reference><Reference><Citation>Geissler WM, Davis DL, Wu L, Bradshaw KD, Patel S, Mendonca BB, et al. Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet. 1994;7:34&#x2013;9. doi: 10.1038/ng0594-34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0594-34</ArticleId><ArticleId IdType="pubmed">8075637</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosler A. 17 beta-hydroxysteroid dehydrogenase 3 deficiency in the Mediterranean population Pediatr. Endocr Rev. 2006;3(3 Suppl):455&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551466</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendonca BB, Gomes NL, Costa EM, Inacio M, Martin RM, Nishi MY, et al. 46,XY disorder of sex development (DSD) due to 17&#x3b2;-hydroxysteroid dehydrogenase type 3 deficiency. J Steroid Biochem Mol Biol. 2017;165:79&#x2013;85. doi: 10.1016/j.jsbmb.2016.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2016.05.002</ArticleId><ArticleId IdType="pubmed">27163392</ArticleId></ArticleIdList></Reference><Reference><Citation>Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol. 2002;198:51&#x2013;9. doi: 10.1016/s0303-7207(02)00368-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0303-7207(02)00368-4</ArticleId><ArticleId IdType="pubmed">12573814</ArticleId></ArticleIdList></Reference><Reference><Citation>Akcay T, Fernandez-Cancio M, Turan S, G&#xfc;ran T, Audi L, Bereket A. AR and SRD5A2 gene mutations in a series of 51 Turkish 46,XY DSD children with a clinical diagnosis of androgen insensitivity. Andrology. 2014;2:572&#x2013;8. doi: 10.1111/j.2047-2927.2014.00215.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2047-2927.2014.00215.x</ArticleId><ArticleId IdType="pubmed">24737579</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer AL, Brinkmann AO, Nijman RM, Verleun-Mooijman MC, de Ruiter P, Niermeijer MF, et al. Phenotypic variation in a family with partial androgen insensitivity syndrome explained by differences in 5 alpha dihydrotestosterone availability. J Clin Endocrinol Metab. 2001;86:1240&#x2013;6. doi: 10.1210/jcem.86.3.7333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.86.3.7333</ArticleId><ArticleId IdType="pubmed">11238515</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, et al. Phenotypical, biological, and molecular heterogeneity of 5&#x3b1;-reductase deficiency: an extensive international experience of 55 patients. J Clin Endocrinol Metab. 2011;96:296&#x2013;307. doi: 10.1210/jc.2010-1024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2010-1024</ArticleId><ArticleId IdType="pubmed">21147889</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AO, But BW, Lee CY, Lam YY, Ng KL, Tung JY, et al. Diagnosis of 5&#x3b1;-reductase 2 deficiency: is measurement of dihydrotestosterone essential? Clin Chem. 2013;59:798&#x2013;806. doi: 10.1373/clinchem.2012.196501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2012.196501</ArticleId><ArticleId IdType="pubmed">23513070</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista RL, Mendonca BB. Integrative and analytical review of the 5-alpha-reductase type 2 deficiency worldwide. Appl Clin Genet. 2020;13:83&#x2013;96. doi: 10.2147/tacg.s198178.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/tacg.s198178</ArticleId><ArticleId IdType="pmc">PMC7167369</ArticleId><ArticleId IdType="pubmed">32346305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata T, Laporte J, Fukami M. MAMLD1 (CXorf6): a new gene involved in hypospadias. Horm Res. 2009;71:245&#x2013;52. doi: 10.1159/000208797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000208797</ArticleId><ArticleId IdType="pubmed">19339788</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Su C, Fan L, Gao F, Liang X, Gong C. Clinical and molecular spectrum of 46,XY disorders of sex development that harbour MAMLD1 variations: case series and review of literature. Orphanet J Rare Dis. 2020;15:188. doi: 10.1186/s13023-020-01459-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-020-01459-9</ArticleId><ArticleId IdType="pmc">PMC7370409</ArticleId><ArticleId IdType="pubmed">32690052</ArticleId></ArticleIdList></Reference><Reference><Citation>Fl&#xfc;ck CE, Aud&#xed; L, Fern&#xe1;ndez-Cancio M, Sauter KS, Mart&#xed;nez de La Piscina I, Casta&#xf1;o L, et al. Broad phenotypes of disorders/differences of sex development in MAMLD1 patients through oligogenic disease. Front Genet. 2019;10:746. doi: 10.3389/fgene.2019.00746.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2019.00746</ArticleId><ArticleId IdType="pmc">PMC6726737</ArticleId><ArticleId IdType="pubmed">31555317</ArticleId></ArticleIdList></Reference><Reference><Citation>Camats N, Fl&#xfc;ck CE, Aud&#xed; L. Oligogenic origin of differences of sex development in humans. Int J Mol Sci. 2020;21:1809. doi: 10.3390/ijms21051809.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21051809</ArticleId><ArticleId IdType="pmc">PMC7084473</ArticleId><ArticleId IdType="pubmed">32155719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalfa N, Liu B, Klein O, Wang MH, Cao M, Baskin LS. Genomic variants of ATF3 in patients with hypospadias. J Urol. 2008;180:2183&#x2013;8. doi: 10.1016/j.juro.2008.07.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2008.07.066</ArticleId><ArticleId IdType="pubmed">18804813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlin A, Zuccarello D, Garolla A, Selice R, Vinanzi C, Ganz F, et al. Mutations in INSL3 and RXFP2 genes in cryptorchid boys. Ann N Y Acad Sci. 2009;1160:213&#x2013;4. doi: 10.1111/j.1749-6632.2008.03784.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2008.03784.x</ArticleId><ArticleId IdType="pubmed">19416190</ArticleId></ArticleIdList></Reference><Reference><Citation>Audi L, Fernandez-Cancio M, Carrascosa A, Andaluz P, Toran N, Pir&#xf3; C, et al. Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XYdisorder of sex development. J Clin Endocrinol Metab. 2010;95:1876&#x2013;88. doi: 10.1210/jc.2009-2146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2009-2146</ArticleId><ArticleId IdType="pubmed">20150575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongan NP, Tadokoro-Cuccaro R, Bunch T, Hughes IA. Androgen insensitivity syndrome. Best Pract Res Clin Endocrinol Metabol. 2015;29:569&#x2013;80. doi: 10.1016/j.beem.2015.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2015.04.005</ArticleId><ArticleId IdType="pubmed">26303084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouvattier C, Carel JC, Lecointre C, David A, Sultan C, Bertrand AM, et al. Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the AR gene. J Clin Endocrinol Metab. 2002;87:29&#x2013;32. doi: 10.1210/jcem.87.1.7923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.87.1.7923</ArticleId><ArticleId IdType="pubmed">11788616</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista RL, Costa EMF, Rodrigues AS, Gomes NL, Faria JA, Nishi MY, et al. Androgen insensitivity syndrome: a review. Arch Endocrinol Metabol. 2018;62:227&#x2013;35. doi: 10.20945/2359-3997000000031.</Citation><ArticleIdList><ArticleId IdType="doi">10.20945/2359-3997000000031</ArticleId><ArticleId IdType="pmc">PMC10118986</ArticleId><ArticleId IdType="pubmed">29768628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Zhu H, Wang N, Han B, Zhao S, Song H, et al. Somatic mosaicism of androgen receptor gene in an androgen insensitivity syndrome patient conceived through assisted reproduction technique. Mol Genet Genomic Med. 2019;7:e00906. doi: 10.1002/mgg3.906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mgg3.906</ArticleId><ArticleId IdType="pmc">PMC6785456</ArticleId><ArticleId IdType="pubmed">31429517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez MF, Olmos B, Granada A, L&#xf3;pez-Espinosa MJ, Molina-Molina JM, Fernandez JM, et al. Human exposure to endocrine-disrupting chemicals and prenatal risk factors for cryptorchidism and hypospadias: a nested case-control study. Environ Health Perspect. 2007;115(1 Suppl):8&#x2013;14. doi: 10.1289/ehp.9351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/ehp.9351</ArticleId><ArticleId IdType="pmc">PMC2174399</ArticleId><ArticleId IdType="pubmed">18174944</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspari L, Sampaio DR, Paris F, Audran F, Orsini M, Neto JB, et al. High prevalence of micropenis in 2710 male newborns from an intensive-use pesticide area of Northeastern Brazil. Int J Androl. 2012;35:253&#x2013;64. doi: 10.1111/j.1365-2605.2011.01241.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2605.2011.01241.x</ArticleId><ArticleId IdType="pubmed">22372605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspari L, Paris F, Philibert P, Audran F, Orsini M, Servant N, et al. Idiopathic&#x2019; partial androgen insensitivity syndrome in 28 newborn and infant males: impact of prenatal exposure to environmental endocrine disruptor chemicals? Eur J Endocrinol. 2011;165:579&#x2013;87. doi: 10.1530/eje-11-0580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje-11-0580</ArticleId><ArticleId IdType="pubmed">21788424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouty A, Ayers KL, Pask A, Heloury Y, Sinclair AH. The genetic and environmental factors underlying hypospadias. Sex Dev. 2015;9:239&#x2013;59. doi: 10.1159/000441988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000441988</ArticleId><ArticleId IdType="pmc">PMC5012964</ArticleId><ArticleId IdType="pubmed">26613581</ArticleId></ArticleIdList></Reference><Reference><Citation>Josso N, Belville C, di Clemente N, Picard JY. AMH and AMH receptor defects in persistent M&#xfc;llerian duct syndrome. Hum Reprod Update. 2005;11:351&#x2013;6. doi: 10.1093/humupd/dmi014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humupd/dmi014</ArticleId><ArticleId IdType="pubmed">15878900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutson JM, Grover SR, O&#x2019;Connell M, Pennell SD. Malformation syndromes associated with disorders of sex development. Nat Rev Endocrinol. 2014;10:476&#x2013;87. doi: 10.1038/nrendo.2014.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2014.83</ArticleId><ArticleId IdType="pubmed">24913517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek N, Miles H, Bunch T, Pilfold-Wilkie V, Tadokoro-Cuccaro R, Davies J, et al. Low frequency of androgen receptor gene mutations in 46,XY DSD, and fetal growth restriction. Arch Dis Child. 2014;99:358&#x2013;61. doi: 10.1136/archdischild-2013-305338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2013-305338</ArticleId><ArticleId IdType="pubmed">24366239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed SF, Bashamboo A, Lucas-Herald A, McElreavey K. Understanding the genetic aetiology in patients with XY DSD. Br Med Bull. 2013;106:67&#x2013;89. doi: 10.1093/bmb/ldt008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldt008</ArticleId><ArticleId IdType="pubmed">23529942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, Edwards Z, et al. Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development. Clin Endocrinol. 2016;84:771&#x2013;88. doi: 10.1111/cen.12857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen.12857</ArticleId><ArticleId IdType="pmc">PMC4855619</ArticleId><ArticleId IdType="pubmed">26270788</ArticleId></ArticleIdList></Reference><Reference><Citation>Baetens D, Mladenov W, Delle Chiaie B, Menten B, Desloovere A, Iotova V, et al. Extensive clinical, hormonal and genetic screening in a large consecutive series of 46,XY neonates and infants with atypical sexual development. Orphanet J Rare Dis. 2014;9:209. doi: 10.1186/s13023-014-0209-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-014-0209-2</ArticleId><ArticleId IdType="pmc">PMC4271496</ArticleId><ArticleId IdType="pubmed">25497574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangalore Krishna K, Houk CP, Lee PA. Pragmatic approach to intersex, including genital ambiguity, in the newborn. Semin Perinatol. 2017;41:244&#x2013;51. doi: 10.1053/j.semperi.2017.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semperi.2017.03.013</ArticleId><ArticleId IdType="pubmed">28535943</ArticleId></ArticleIdList></Reference><Reference><Citation>Le&#xf3;n NY, Reyes AP, Harley VR. A clinical algorithm to diagnose differences of sex development. Lancet Diabetes Endocrinol. 2019;7:560&#x2013;74. doi: 10.1016/s2213-8587(18)30339-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-8587(18)30339-5</ArticleId><ArticleId IdType="pubmed">30803928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriakou A, Lucas-Herald AK, McGowan R, Tobias ES, Ahmed SF. Disorders of sex development: advances in genetic diagnosis and challenges in management. Adv Genom Genet. 2015;5:165&#x2013;77.</Citation></Reference><Reference><Citation>Yatsenko SA, Witchel SF. Genetic approach to ambiguous genitalia and disorders of sex development: what clinicians need to know. Semin Perinatol. 2017;41:232&#x2013;43. doi: 10.1053/j.semperi.2017.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semperi.2017.03.016</ArticleId><ArticleId IdType="pubmed">28545654</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R, Cerqueira V, Kyriakou A, Lucas-Herald A, McNeilly J, McMillan M, et al. Prevalence of endocrine and genetic abnormalities in boys evaluated systematically for a disorder of sex development. Hum Reprod. 2017;32:2130&#x2013;7. doi: 10.1093/humrep/dex280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/dex280</ArticleId><ArticleId IdType="pmc">PMC5850224</ArticleId><ArticleId IdType="pubmed">28938747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolesinska Z, Acierno J, Ahmed SF, Xu C, Kapczuk K, Skorczyk-Werner A, et al. Integrating clinical and genetic approaches in the diagnosis of 46,XY disorders of sex development. Endocrinol Connect. 2018;7:1480&#x2013;90. doi: 10.1530/ec-18-0472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ec-18-0472</ArticleId><ArticleId IdType="pmc">PMC6311460</ArticleId><ArticleId IdType="pubmed">30496128</ArticleId></ArticleIdList></Reference><Reference><Citation>Audi L, Ahmed SF, Krone N, Cools M, McElreavey K, Holterhus PM, et al. Genetics IN endocrinology: approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (DSD): position paper of EU COST Action BM 1303 &#x2018;DSDnet&#x2019;. Eur J Endocrinol. 2018;179:R197&#x2013;206. doi: 10.1530/eje-18-0256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje-18-0256</ArticleId><ArticleId IdType="pmc">PMC6182188</ArticleId><ArticleId IdType="pubmed">30299888</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>